Understanding the differentiation syndrome in acute promyelocytic leukemia: a comprehensive updated review.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 750, doi. 10.1007/s10637-025-01556-1
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2025 AND VI 43 AND IP 3
Results: 23
1
2
Research progress on cancer-related epigenetic switches.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 525, doi. 10.1007/s10637-025-01555-2
- By:
- Publication type:
- Article
3
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 719, doi. 10.1007/s10637-025-01554-3
- By:
- Publication type:
- Article
4
Clinical characterizations, management, and prognosis in immune checkpoint inhibitor-induced myelitis.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 742, doi. 10.1007/s10637-025-01553-4
- By:
- Publication type:
- Article
5
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 728, doi. 10.1007/s10637-025-01550-7
- By:
- Publication type:
- Article
6
Approval of high-benefit oncology drugs in Japan: utilization of expedited regulatory pathways for the accelerated approved anticancer drugs.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 701, doi. 10.1007/s10637-025-01549-0
- By:
- Publication type:
- Article
7
Orelabrutinib combined with rituximab and high-dose methotrexate as induction therapy in newly diagnosed primary central nervous system lymphoma.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 679, doi. 10.1007/s10637-025-01548-1
- By:
- Publication type:
- Article
8
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 709, doi. 10.1007/s10637-025-01547-2
- By:
- Publication type:
- Article
9
The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 687, doi. 10.1007/s10637-025-01546-3
- By:
- Publication type:
- Article
10
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 669, doi. 10.1007/s10637-025-01545-4
- By:
- Publication type:
- Article
11
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 609, doi. 10.1007/s10637-025-01538-3
- By:
- Publication type:
- Article
12
Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 451, doi. 10.1007/s10637-025-01542-7
- By:
- Publication type:
- Article
13
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 646, doi. 10.1007/s10637-025-01541-8
- By:
- Publication type:
- Article
14
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 634, doi. 10.1007/s10637-025-01540-9
- By:
- Publication type:
- Article
15
Discovery of potent CRBN-recruiting epidermal growth factor receptor (EGFR) degraders in vitro.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 560, doi. 10.1007/s10637-025-01539-2
- By:
- Publication type:
- Article
16
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 656, doi. 10.1007/s10637-025-01544-5
- By:
- Publication type:
- Article
17
Retrospective analysis of clinical features of pembrolizumab induced psoriasis.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 582, doi. 10.1007/s10637-025-01536-5
- By:
- Publication type:
- Article
18
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 621, doi. 10.1007/s10637-025-01535-6
- By:
- Publication type:
- Article
19
MicroRNA nanoformulation: a promising approach to anti-tumour activity.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 504, doi. 10.1007/s10637-025-01534-7
- By:
- Publication type:
- Article
20
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 588, doi. 10.1007/s10637-025-01530-x
- By:
- Publication type:
- Article
21
Medulloblastoma associated with Lynch syndrome: a case report of germline MLH1 variant and tumor molecular characterization.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 460, doi. 10.1007/s10637-025-01527-6
- By:
- Publication type:
- Article
22
Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 466, doi. 10.1007/s10637-025-01525-8
- By:
- Publication type:
- Article
23
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.
- Published in:
- Investigational New Drugs, 2025, v. 43, n. 3, p. 602, doi. 10.1007/s10637-024-01498-0
- By:
- Publication type:
- Article